Nutriband Inc. provided shareholders with updates following its 2026 Annual Shareholders Meeting, highlighting board appointments and substantial progress in developing its abuse-deterrent fentanyl patch technology. The company appointed Alessandro Puddu and Viorica Carlig as new directors, strengthening its leadership as it advances its pharmaceutical pipeline.
During 2025, Nutriband strengthened its exclusive partnership with Kindeva, completed commercial manufacturing scale-up, and expanded global patent protection for its AVERSA™ technology. The company secured new patents in the United States and Macao, extending its intellectual property portfolio for the abuse-deterrent transdermal technology. Nutriband also engaged with the U.S. Food and Drug Administration through a Type C meeting and advanced branding initiatives for AVERSA™ FENTANYL, positioning the product for future market entry.
The company's lead product under development is an abuse-deterrent fentanyl patch incorporating AVERSA™ technology, which can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This technology addresses a critical public health concern as fentanyl abuse continues to contribute to the opioid crisis, with traditional transdermal patches being vulnerable to extraction and misuse.
Looking ahead to 2026, Nutriband plans to advance toward a New Drug Application filing by extending patent protection potentially to 2046, manufacturing clinical supplies, filing an Investigational New Drug application, and initiating a Human Abuse Liability clinical study. These steps represent significant milestones in the regulatory pathway for pharmaceutical products and demonstrate the company's commitment to bringing its abuse-deterrent technology to market.
The development of abuse-deterrent formulations represents an important frontier in pharmaceutical innovation, particularly for opioids where misuse remains a significant public health challenge. Nutriband's progress with AVERSA™ technology could potentially establish new standards for transdermal drug delivery safety and create barriers against substance abuse. For business leaders and investors, the company's expanded patent protection and regulatory advancements suggest growing intellectual property value and reduced competitive threats in the abuse-deterrent pharmaceutical space.
Nutriband's latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB. The company's developments in transdermal pharmaceutical products reflect broader trends in biotechnology innovation focused on addressing substance abuse through technological solutions rather than solely through regulatory or educational approaches.
